Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining

被引:36
作者
Medina-Franco, JL
Golbraikh, A
Oloff, S
Castillo, R
Tropsha, A
机构
[1] Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
[2] Univ Nacl Autonoma Mexico, Fac Quim, Dept Farm, Mexico City 04510, DF, Mexico
关键词
database mining; docking; HIV-1; kNN-QSAR; non-nucleoside inhibitors; reverse transcriptase;
D O I
10.1007/s10822-005-4789-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have developed quantitative structure-activity relationship (QSAR) models for 44 non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) of the pyridinone derivative type. The k nearest neighbor (kNN) variable selection approach was used. This method utilizes multiple descriptors such as molecular connectivity indices, which are derived from two-dimensional molecular topology. The modeling process entailed extensive validation including the randomization of the target property (Y-randomization) test and the division of the dataset into multiple training and test sets to establish the external predictive power of the training set models. QSAR models with high internal and external accuracy were generated, with leave-one-out cross-validated R-2 (q(2)) values ranging between 0.5 and 0.8 for the training sets and R-2 values exceeding 0.6 for the test sets. The best models with the highest internal and external predictive power were used to search the National Cancer Institute database. Derivatives of the pyrazolo[3,4-d]pyrimidine and phenothiazine type were identified as promising novel NNRTIs leads. Several candidates were docked into the binding pocket of nevirapine with the AutoDock (version 3.0) software. Docking results suggested that these types of compounds could be binding in the NNRTI binding site in a similar mode to a known non-nucleoside inhibitor nevirapine.
引用
收藏
页码:229 / 242
页数:14
相关论文
共 52 条
  • [1] Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs (vol 41, pg 150, 1998)
    Chan, C
    Yin, H
    Garforth, J
    McKie, JH
    Jaouhari, R
    Speers, P
    Douglas, KT
    Rock, PJ
    Yardley, V
    Croft, SL
    Fairlamb, AH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) : 4910 - 4910
  • [2] 2-amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1
    Chan, JH
    Hong, JS
    Hunter, RN
    Orr, GF
    Cowan, JR
    Sherman, DB
    Sparks, SM
    Reitter, BE
    Andrews, CW
    Hazen, RJ
    St Clair, M
    Boone, LR
    Ferris, RG
    Creech, KL
    Roberts, GB
    Short, SA
    Weaver, K
    Ott, RJ
    Ren, JS
    Hopkins, A
    Stuart, DI
    Stammers, DK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (12) : 1866 - 1882
  • [3] POTENTIAL PURINE ANTAGONISTS .6. SYNTHESIS OF 1-ALKYL-4-SUBSTITUTED AND 1-ARYL-4-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINES
    CHENG, CC
    ROBINS, RK
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1956, 21 (11) : 1240 - 1256
  • [4] Cho S.J., 1999, RATIONAL DRUG DESIGN, P198
  • [5] VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD
    CLARK, M
    CRAMER, RD
    VANOPDENBOSCH, N
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) : 982 - 1012
  • [6] Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
    Das, K
    Clark, AD
    Lewi, PJ
    Heeres, J
    de Jonge, MR
    Koymans, LMH
    Vinkers, HM
    Daeyaert, F
    Ludovici, DW
    Kukla, MJ
    De Corte, B
    Kavash, RW
    Ho, CY
    Ye, H
    Lichtenstein, MA
    Andries, K
    Pauwels, R
    de Béthune, MP
    Boyer, PL
    Clark, P
    Hughes, SH
    Janssen, PAJ
    Arnold, E
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) : 2550 - 2560
  • [7] PLASMA VIREMIA AS A SENSITIVE INDICATOR OF THE ANTIRETROVIRAL ACTIVITY OF L-697,661
    DAVEY, RT
    DEWAR, RL
    REED, GF
    VASUDEVACHARI, MB
    POLIS, MA
    KOVACS, JA
    FALLOON, J
    WALKER, RE
    MASUR, H
    HANEIWICH, SE
    ONEILL, DG
    DECKER, MR
    METCALF, JA
    DELORIA, MA
    LASKIN, OL
    SALZMAN, N
    LANE, HC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5608 - 5612
  • [8] HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches
    De Clercq, E
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (09) : 1800 - 1822
  • [9] MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS
    ESNOUF, R
    REN, JS
    ROSS, C
    JONES, Y
    STAMMERS, D
    STUART, D
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (04): : 303 - 308
  • [10] Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
    Esnouf, RM
    Ren, JS
    Hopkins, AL
    Ross, CK
    Jones, EY
    Stammers, DK
    Stuart, DI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3984 - 3989